
Raffaella Greco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5323496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. Blood Advances, 2022, 6, 3053-3057.	2.5	7
2	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. Bone Marrow Transplantation, 2022, 57, 678-680.	1.3	4
3	The first steps towards a diverse and inclusive EBMT: a position paper. Bone Marrow Transplantation, 2022, 57, 343-346.	1.3	2
4	Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 1106.	1.0	8
5	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. Frontiers in Oncology, 2022, 12, 850403.	1.3	1
6	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	1.3	45
7	Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases (Taylor &) Tj ETQq1	1 0.7843 1.3	l4rgBT /Ov€ 0
8	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	1.2	3
9	Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2022, 57, 1055-1062.	1.3	16
10	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 2022, 57, 1217-1239.	1.3	119
11	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	1.3	10
12	Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients. Blood, 2021, 137, 1556-1559.	0.6	18
13	Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annual Review of Medicine, 2021, 72, 215-228.	5.0	44
14	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 2021, 96, .	1.5	36
15	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. American Journal of Transplantation, 2021, 21, 1622-1628.	2.6	35
16	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	1.3	221
17	Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome. Frontiers in Immunology, 2021, 12, 670822.	2.2	0
18	The Effect of Removable Orthodontic Appliances on Oral Microbiota: A Systematic Review. Applied Sciences (Switzerland), 2021, 11, 2881.	1.3	9

#	Article	IF	CITATIONS
19	Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Fungi (Basel, Switzerland), 2021, 7, 347.	1.5	5
20	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 2021, 56, 1493-1508.	1.3	27
21	Autologous Hematopoietic Stem Cell Transplantation for Behçet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Frontiers in Immunology, 2021, 12, 638709.	2.2	6
22	COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome. Bone Marrow Transplantation, 2021, 56, 2312-2315.	1.3	7
23	The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. International Journal of Antimicrobial Agents, 2021, 57, 106335.	1.1	9
24	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. Frontiers in Oncology, 2021, 11, 705568.	1.3	4
25	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. Frontiers in Oncology, 2021, 11, 731478.	1.3	8
26	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2021, 27, 776.e1-776.e13.	0.6	26
27	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Postâ€transplant cyclophosphamide to overcome the HLAâ€matching barrier. Transplant Infectious Disease, 2021, 23, e13551.	0.7	Ο
28	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Frontiers in Oncology, 2021, 11, 722436.	1.3	6
29	Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2021, , .	1.3	1
30	Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. Haematologica, 2021, 106, 1480-1483.	1.7	5
31	Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party. Frontiers in Immunology, 2021, 12, 813957.	2.2	22
32	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	1.3	128
33	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 316-322.	2.0	4
34	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in	1.1	8
35	Neurology, 2020, 11, 556141. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Annals of Hematology, 2020, 99, 867-875.	0.8	8
36	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biology of Blood and Marrow Transplantation, 2020, 26, 1179-1188.	2.0	49

#	Article	IF	CITATIONS
37	Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Frontiers in Immunology, 2020, 11, 524.	2.2	100
38	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	33
39	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Frontiers in Immunology, 2019, 10, 1570.	2.2	48
40	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. Frontiers in Immunology, 2019, 10, 2319.	2.2	25
41	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019048.	0.5	9
42	Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease. Bone Marrow Transplantation, 2019, 54, 1145-1147.	1.3	7
43	General information for patients and carers considering haematopoletic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow	1.3	25
44	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	5.8	120
45	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	15.2	253
46	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	1.3	8
47	Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. Clinical Hematology International, 2019, 1, 120-123.	0.7	2
48	CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study. Blood, 2019, 134, 4536-4536.	0.6	0
49	Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1476-1482.	2.0	39
50	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	1.3	10
51	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. Bone Marrow Transplantation, 2018, 53, 410-416.	1.3	10
52	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation, 2018, 53, 1522-1531.	1.3	22
53	CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, S297.	2.0	0
54	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	0.6	164

#	Article	IF	CITATIONS
55	Total marrow irradiation (TMI) combined with treosulfan and fludarabine conditioning regimen for chemosensitive advanced multiple myeloma (MM) patients undergoing matched allogeneic stem-cell transplantation: First results of a phase I/II prospective monocentric study (TrRaMM TMI) Journal of Clinical Oncology, 2018, 36, e19019-e19019.	0.8	0
56	Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. Blood, 2018, 132, 2028-2028.	0.6	1
57	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. Blood, 2018, 132, 3381-3381.	0.6	0
58	Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients. Blood, 2018, 132, 4600-4600.	0.6	1
59	Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning. Blood, 2018, 132, 4662-4662.	0.6	0
60	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. Expert Review of Hematology, 2017, 10, 479-492.	1.0	34
61	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	1.4	4
62	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American Journal of Hematology, 2017, 92, 1011-1019.	2.0	14
63	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2151-2158.	2.0	9
64	Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 114-119.	1.3	33
65	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. Open Forum Infectious Diseases, 2017, 4, ofx215.	0.4	45
66	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	2.9	103
67	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	2.5	151
68	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica, 2016, 101, e157-e161.	1.7	55
69	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2016, 51, 1022-1024.	1.3	6
70	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. Biology of Blood and Marrow Transplantation, 2016, 22, 2250-2255.	2.0	36
71	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood, 2016, 128, 1528-1531.	0.6	46
72	Secondary SOLID Tumors after Allogeneic STEM CELL Transplantation: A CROSS-Sectional Evaluation in 260 Adults at 1-Year Follow-up. Biology of Blood and Marrow Transplantation, 2016, 22, S189-S190.	2.0	0

#	Article	IF	CITATIONS
73	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplantation, 2016, 51, 466-469.	1.3	6
74	Escalated Dose-Rates of Total Marrow Irradiation (TMI) Combined with Treosulfan and Fludarabine-Based Conditioning Chemotherapy Regimen for Chemosensitive Advanced Multiple Myeloma (MM) Patients Undergoing a Matched Allogeneic Stem-Cell Transplantation: First Results of a Phase I/II Prospective Monocentric Study (TrRaMM TMI). Blood, 2016, 128, 2221-2221.	0.6	1
75	Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients. Blood, 2016, 128, 3442-3442.	0.6	1
76	Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT. Blood, 2016, 128, 4564-4564.	0.6	3
77	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT), Blood, 2016, 128, 4599-4599.	0.6	3
78	Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia. Blood, 2016, 128, 5810-5810.	0.6	1
79	Longitudinal Microbiome Profile in Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 100 Patients. Blood, 2016, 128, 3435-3435.	0.6	О
80	Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 3492-3492.	0.6	0
81	How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party. Blood, 2016, 128, 4581-4581.	0.6	Ο
82	Pre-Transplant Colonization By a Multidrug-Resistant Gram Negative Bacteria Has No Impact on Overall Survival and Mortality after Hematopoietic Stem Cell Transplantation: A Single-Center Experience in 362 Patients. Blood, 2016, 128, 5743-5743.	0.6	0
83	Pentraxin 3 As a Novel Diagnostic and Prognostic Biomarker for Acute GvHD and Fungal Infections in Adult Allogeneic HSCT Recipients. Blood, 2016, 128, 4600-4600.	0.6	1
84	Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients. Blood, 2016, 128, 2240-2240.	0.6	0
85	HHV6 Specific T-Cells Are Predictive Biomarker of Active HHV6 Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 213 Patients. Blood, 2016, 128, 3399-3399.	0.6	Ο
86	Infection-Related Mortality (IRM) after Allogeneic Hematopoietic Stem Cell Transplantation: Age, CMV Status, Pre-Transplant IgA and IgM Levels Predict IRM and Survival in a New Clinico-Biological Scoring System Developed in 492 Consecutive Patients. Blood, 2016, 128, 2220-2220.	0.6	1
87	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. Blood, 2016, 128, 4567-4567.	0.6	О
88	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood, 2015, 125, 2865-2874.	0.6	119
89	Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology, 2015, 6, 95.	1.6	102
90	Haploidentical HSCT: a 15-year experience at San Raffaele. Bone Marrow Transplantation, 2015, 50, S67-S71.	1.3	6

#	Article	IF	CITATIONS
91	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
92	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Science Translational Medicine, 2015, 7, 317ra198.	5.8	102
93	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia, 2015, 29, 1143-1152.	3.3	110
94	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	1.4	56
95	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplantation, 2015, 50, 173-180.	1.3	71
96	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplantation, 2015, 50, 1262-1264.	1.3	11
97	HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics. Blood, 2015, 126, 743-743.	0.6	2
98	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. Blood, 2015, 126, 4362-4362.	0.6	0
99	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. Blood, 2015, 126, 5465-5465.	0.6	0
100	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. Blood, 2015, 126, 263-263.	0.6	0
101	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Frontiers in Immunology, 2014, 5, 16.	2.2	126
102	Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational propensity score-matched study. Expert Review of Molecular Diagnostics, 2014, 14, 623-632.	1.5	8
103	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	2.8	43
104	Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2014, 14, 478.	2.0	24
105	Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in High Risk Haematological Diseases: A 10-Years Evaluation at San Raffaele Scientific Institute. Blood, 2014, 124, 2498-2498.	0.6	6
106	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. Blood, 2014, 124, 2535-2535.	0.6	5
107	Sirolimus and Post Transplant Cyclophosphamide (PT-Cy) Allow the Use of Haploidentical PBSC Grafts Inducing a Favorable Immune Reconstitution with Low Rates of GvHD: Results in 39 Patients. Blood, 2014, 124, 2584-2584.	0.6	1
108	Droplet Digital PCR for DNMT3A and IDH1/2 Mutations to Improve Early Diagnosis of Acute Myeloid Leukemia Relapse after Allogeneic HSCT. Blood, 2014, 124, 3951-3951.	0.6	1

#	Article	IF	CITATIONS
109	GvHD Kinetics after Haploidentical TK-Cells: In-Vivo HSV-TK Suicide Machinery Is Effective in GvHD Control and Provide a Long-Term Immune-Suppressive Treatment-Free Survival. Blood, 2014, 124, 548-548.	0.6	2
110	Efficacy of HSV-TK ⁺ suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT): Preliminary results of randomized TK008 study Journal of Clinical Oncology, 2014, 32, 7003-7003.	0.8	1
111	Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 192-192.	0.6	0
112	Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia. Blood, 2014, 124, 2750-2750.	0.6	0
113	Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan-Based Conditioning Regimen for Acute Leukemia Relapsing after Initial Allogeneic Transplantation. Blood, 2014, 124, 3956-3956.	0.6	4
114	Human Herpes Virus 6 Infection in 54 Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Manifestations and Outcome. Blood, 2014, 124, 3899-3899.	0.6	0
115	Clinical and immunologic responses in melanoma patients vaccinated with MAGEâ€A3â€genetically modified lymphocytes. International Journal of Cancer, 2013, 132, 2557-2566.	2.3	20
116	Post-Transplant Cyclophosphamide Haplo-HSCT Revised: Peripheral Blood Stem Cell Graft and Sirolimus To Enhance Immune Reconstitution and Graft Versus Leukemia Effect In Patients With Active Leukemia. Blood, 2013, 122, 2118-2118.	0.6	2
117	Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil. Blood, 2013, 122, 2125-2125.	0.6	3
118	Intensification Of Treosulfan and Fludarabine-Based Conditioning With 4 Gy TBI For Allogeneic Stem Cell Transplantation In Patients With Hematological Malignancies. Blood, 2013, 122, 2149-2149.	0.6	0
119	Long-Term Immunological Profile and T Cell Dynamics In Patients Treated With Allogeneic Transplantation and TK-Cells For Hematological Malignancies. Blood, 2013, 122, 165-165.	0.6	0
120	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Current Opinion in Hematology, 2012, 19, 427-433.	1.2	30
121	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood, 2012, 120, 1820-1830.	0.6	47
122	TK-Cells Safety and Efficacy in Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Clinical and Molecular Assessment in 128 Treated Patients Blood, 2012, 120, 3061-3061.	0.6	0
123	Human Herpes Virus-6 and Clinical Manifestations After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1960-1960.	0.6	0
124	Implementation of An Alternative Donor Option Is Prerequisite for a Good Intention-to-Treat (ITT) In Patients In Need of Allogeneic Transplantation: Analysis of 410 Patients. Blood, 2010, 116, 2382-2382.	0.6	0
125	Thymic Renewal and Anti-Leukemic Effect In Adults After Haploidentical Transplantation and Donor T Cell Suicide Gene Therapy. Blood, 2010, 116, 833-833.	0.6	0
126	Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution. Blood, 2010, 116, 2385-2385.	0.6	17

#	Article	IF	CITATIONS
127	Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 45-45.	0.6	12